Chemistry:Elsulfavirine
 | |
| Clinical data | |
|---|---|
| Trade names | Elpida |
| Other names | VM 1500; elpivirine |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H17BrCl2FN3O5S |
| Molar mass | 629.28 g·mol−1 |
| |
Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).[1][2][3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A).[4] It was developed by the Russian company Viriom.[5]
In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs.[4][6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir.[7]
Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation.[8][9]
In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication.[5]
References
- ↑ "Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment". Expert Opinion on Drug Metabolism & Toxicology 15 (10): 813–829. October 2019. doi:10.1080/17425255.2019.1673367. PMID 31556749.
- ↑ "Emerging reverse transcriptase inhibitors for HIV-1 infection". Expert Opinion on Emerging Drugs 23 (2): 149–157. June 2018. doi:10.1080/14728214.2018.1474202. PMID 29737220.
- ↑ "Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment". Expert Opinion on Drug Metabolism & Toxicology 15 (10): 813–829. October 2019. doi:10.1080/17425255.2019.1673367. PMID 31556749.
- ↑ 4.0 4.1 "Elsulfavirine: First Global Approval". Drugs 77 (16): 1811–1816. October 2017. doi:10.1007/s40265-017-0820-3. PMID 28940154.
- ↑ 5.0 5.1 "Elsulfavirine - Viriom". AdisInsight. https://adisinsight.springer.com/drugs/800031212.
- ↑ "Chapter 29: To Market, To Market--2017". 2018 Medicinal Chemistry Reviews 53. https://www.acsmedchem.org/?nd=mcr5329.
- ↑ "Elpida (elsulfavirine) becomes the preferred first line therapy for treatment of HIV infection in Russia" (Press release). PRN Newswire. February 2, 2021.
- ↑ "What's in the Pipeline?". Contagion 4 (3). June 5, 201. https://www.contagionlive.com/view/whats-in-the-pipeline.
- ↑ "Pre-clinical pharmacokinetics of elsufavirine/VM1500A long acting injectable formulations". International Antiviral Society-USA. 2017. Poster WEPEA0190.
 |  |
